Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCT-100 in Relapsed/Refractory Pediatric Cancers
NCT03455140Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of arginase-1 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), neuroblastoma and 2 more (4 arms), sponsored by University of Birmingham. Primary endpoints: Recommended Phase II Dose at 28 days and Disease Response at 8 weeks. Started Aug 2018; status: completed.
02
Drugs
arginase-1
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)neuroblastomasarcomahigh-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03455140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455140.